

Astellas Announces Management Structure Change

Tokyo, March 1, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the management structure changes effective April 1, 2016 as below.

【1】 Top Management Structure

Top Management	Divisional/Functional Responsibilities
Yoshihiko Hatanaka CEO	Internal Auditing, Drug Discovery Research, Technology, Japan Sales & Marketing, Asia/Oceania Business, EMEA Operations, Americas Operations, MS Ocata Therapeutics, Inc.
Yoshirou Miyokawa CAO & CCO	External Relations, General Affairs, Human Resources, Legal, Ethics & Compliance, Executive Office
Yasumasa Masuda CFO	Corporate Finance & Control, Accounting & Tax, Corporate Communications, Procurement, Information Systems
Kenji Yasukawa CSTO	Corporate Planning, Healthcare Policy & CSR, Product & Portfolio Strategy, Business Development, Innovation Management, Evolving Medical Solutions, Intellectual Property, RWI
Sef Kurstjens CMO	Dev, PV, MA, RA, CRQA, QA

CEO: Chief Executive Officer

CAO: Chief Administrative Officer

CCO: Chief Compliance Officer

CFO: Chief Financial Officer

CSTO: Chief Strategy Officer

CMO: Chief Medical Officer

EMEA: Europe, Middle East and Africa

MS: Marketing Strategy

RWI: Real World Informatics and Analytics

Dev: Development

PV: Pharmacovigilance

MA: Medical Affairs

RA: Regulatory Affairs

CRQA: Clinical and Research Quality Assurance

QA: Quality Assurance

【2】 Global Function

Enhancement of Compliance

To further enhance global compliance initiatives, the legal and compliance functions will be divided structurally in all regions. A new function “Ethics & Compliance” which will globally integrate and manage the regional Ethics & Compliance functions in Japan, Americas, EMEA and Asia/Oceania regions will be established. The Head of Ethics & Compliance will report directly to CCO.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

###

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: 03-3244-3201 FAX: 03-5201-7473 http://www.astellas.com/en